Display options
Share it on

Can J Psychiatry. 2019 Oct;64(10):680-685. doi: 10.1177/0706743719870515. Epub 2019 Aug 21.

The Core Deficit of Classical Schizophrenia: Implications for Predicting the Functional Outcome of Psychotic Illness and Developing Effective Treatments.

Canadian journal of psychiatry. Revue canadienne de psychiatrie

Peter F Liddle

Affiliations

  1. Division of Psychiatry and Applied Psychology, Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.

PMID: 31434513 PMCID: PMC6783668 DOI: 10.1177/0706743719870515

Abstract

Many people suffering from psychotic illnesses experience persisting impairment of occupational and social function. Evidence assembled since the classical description of schizophrenia over a century ago indicates that both disorganization and impoverishment of mental activity are associated with persisting impairment. Longitudinal studies of young people at risk of schizophrenia reveal that both mental impoverishment and disorganization predict poor long-term outcome. These clinical features are related to cognitive impairments. Evidence from brain imaging indicates overlap in the brain abnormalities implicated in these phenomena, including impaired function of long-range connections between sensory cortex and the salience network, a network engaged in recruiting cerebral systems for processing of information salient to current circumstances. The evidence suggests that the common features underlying these two groups of symptoms might reflect a core pathological process distinguishing nonaffective from affective psychosis. This pathological process might therefore justifiably be designated the "core deficit" of classical schizophrenia. To develop more effective treatments to prevent persisting disability, we require the ability to identify individuals at risk at an early stage. Recent studies provide pointers toward effective strategies for identifying cases at risk of poor outcome. Accumulating evidence confirms that appreciable potential for neuroplastic change in the brain persists into adult life. Furthermore, brain function can be enhanced by targeted neuromodulation treatments. We now have promising tools not only for investigating the psychological and neural mechanisms that underlie persisting functional impairment but also for identifying individuals at risk and for harnessing brain plasticity to improve treatment.

Keywords: core deficit; disorganization; negative symptoms; neuroplasticity; outcome; psychomotor poverty; psychosis; salience network; schizophrenia; treatment

References

  1. Schizophr Res. 2011 Sep;131(1-3):152-6 - PubMed
  2. J Pers Assess. 2006 Dec;87(3):292-304 - PubMed
  3. Nature. 2004 Jan 22;427(6972):311-2 - PubMed
  4. PLoS One. 2014 Apr 04;9(4):e93994 - PubMed
  5. Lancet. 1976 Oct 30;2(7992):924-6 - PubMed
  6. Arch Gen Psychiatry. 2007 May;64(5):532-42 - PubMed
  7. Schizophr Bull. 1985;11(3):409-19 - PubMed
  8. Schizophr Bull. 1986;12(3):394-407 - PubMed
  9. NPJ Schizophr. 2017 Apr 13;3:18 - PubMed
  10. Br J Psychiatry. 1982 Dec;141:567-72 - PubMed
  11. Neuroimage. 2010 Jan 15;49(2):1153-60 - PubMed
  12. Br J Psychiatry. 2017 Dec;211(6):350-358 - PubMed
  13. Am J Psychiatry. 2010 Sep;167(9):1075-82 - PubMed
  14. Br J Psychiatry. 1991 Mar;158:317-22 - PubMed
  15. Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12569-74 - PubMed
  16. Arch Gen Psychiatry. 1982 Jul;39(7):784-8 - PubMed
  17. Br J Psychiatry. 1987 Aug;151:145-51 - PubMed
  18. Biol Psychiatry. 2018 Nov 1;84(9):665-674 - PubMed
  19. J Clin Psychopharmacol. 2018 Oct;38(5):513-519 - PubMed
  20. Schizophr Bull. 1991;17(4):555-64 - PubMed
  21. J Neurosci. 2010 Mar 3;30(9):3297-303 - PubMed
  22. Lancet. 1978 Apr 22;1(8069):848-51 - PubMed
  23. Br J Psychiatry. 1992 Feb;160:179-86 - PubMed
  24. Br J Psychiatry. 1991 Mar;158:340-5 - PubMed
  25. Neuropsychopharmacology. 2013 Aug;38(9):1808-15 - PubMed
  26. Nat Neurosci. 2009 Nov;12(11):1370-1 - PubMed
  27. Sci Rep. 2014 Jan 15;4:3691 - PubMed
  28. J Neurosci. 2016 Jun 15;36(24):6365-7 - PubMed
  29. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:112-120 - PubMed
  30. Psychol Med. 1998 Jul;28(4):935-47 - PubMed
  31. Brain. 2012 Jan;135(Pt 1):276-84 - PubMed
  32. Schizophr Bull. 2019 Jun 18;45(4):883-891 - PubMed
  33. Am J Psychiatry. 2011 May;168(5):472-85 - PubMed
  34. Br Med J. 1980 Jan 12;280(6207):66-8 - PubMed
  35. JAMA Psychiatry. 2018 Nov 1;75(11):1156-1172 - PubMed
  36. Neuroimage Clin. 2015 Sep 25;12:869-878 - PubMed
  37. Br J Psychiatry. 2002 Oct;181:326-30 - PubMed
  38. Neuron. 2013 Aug 21;79(4):814-28 - PubMed
  39. NPJ Schizophr. 2015 Aug 26;1:15030 - PubMed
  40. Neuroimage. 2019 Jan 15;185:425-433 - PubMed

MeSH terms

Publication Types

Grant support